186 related articles for article (PubMed ID: 11472609)
1. Single-center experience with mycophenolate mofetil in pediatric renal transplant recipients.
Virji M; Carter JE; Lirenman DS
Pediatr Transplant; 2001 Aug; 5(4):293-6. PubMed ID: 11472609
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience.
Dipchand AI; Benson L; McCrindle BW; Coles J; West L
Pediatr Transplant; 2001 Apr; 5(2):112-8. PubMed ID: 11328549
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
Sollinger HW
Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group.
Mycophenolate Mofetil Acute Renal Rejection Study Group
Transplantation; 2001 Apr; 71(8):1091-7. PubMed ID: 11374408
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil suspension in pediatric renal transplantation: three-year data from the tricontinental trial.
Höcker B; Weber LT; Bunchman T; Rashford M; Tönshoff B;
Pediatr Transplant; 2005 Aug; 9(4):504-11. PubMed ID: 16048604
[TBL] [Abstract][Full Text] [Related]
6. Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients.
Vasquez EM; Sifontis NM; Pollak R; Benedetti E
Clin Transplant; 2001 Aug; 15(4):253-7. PubMed ID: 11683819
[TBL] [Abstract][Full Text] [Related]
7. Analysis of a single-center experience with mycophenolate mofetil based immunosuppression in renal transplantation.
Triemer HL; Pearson TC; Odom KL; Larsen CP
Clin Transplant; 2000 Aug; 14(4 Pt 2):413-20. PubMed ID: 10946781
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil without antibody induction in cadaver vs. living donor pediatric renal transplantation.
Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W
Pediatr Transplant; 2003 Apr; 7(2):137-41. PubMed ID: 12654055
[TBL] [Abstract][Full Text] [Related]
9. Introduction of mycophenolate mofetil and cyclosporin reduction in children with chronic transplant nephropathy.
David-Neto E; Araujo LM; Lemos FC; David DS; Mazzucchi E; Nahas WC; Arap S; Ianhez LE
Pediatr Transplant; 2001 Aug; 5(4):302-9. PubMed ID: 11472611
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil in liver transplantation.
McDiarmid SV
Clin Transplant; 1996 Feb; 10(1 Pt 2):140-5. PubMed ID: 8680052
[TBL] [Abstract][Full Text] [Related]
11. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
Grinyó JM; Gil-Vernet S; Seron D; Hueso M; Fulladosa X; Cruzado JM; Moreso F; Fernandez A; Torras J; Riera L; Castelao AM; Alsina J
Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. The Mycophenolate Mofetil Renal Refractory Rejection Study Group.
Transplantation; 1996 Mar; 61(5):722-9. PubMed ID: 8607174
[TBL] [Abstract][Full Text] [Related]
13. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients.
Roberti I; Reisman L
Pediatr Transplant; 1999 Aug; 3(3):231-5. PubMed ID: 10487285
[TBL] [Abstract][Full Text] [Related]
15. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
16. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group.
Staskewitz A; Kirste G; Tönshoff B; Weber LT; Böswald M; Burghard R; Helmchen U; Brandis M; Zimmerhackl LB
Transplantation; 2001 Mar; 71(5):638-44. PubMed ID: 11292293
[TBL] [Abstract][Full Text] [Related]
18. What is the role for mycophenolate mofetil in pediatric renal transplantation?
Neu AM; Benfield M
Pediatr Transplant; 1999 Feb; 3(1):83-7. PubMed ID: 10359037
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients.
Aw MM; Verma A; Rela M; Heaton N; Mieli-Vergani G; Dhawan A
Liver Transpl; 2008 Sep; 14(9):1303-8. PubMed ID: 18756458
[TBL] [Abstract][Full Text] [Related]
20. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
